Higher concentrations of serum iron and transferrin saturation but not serum ferritin are associated with cancer outcomes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

© 2016 American Society for Nutrition.
Background: Although the carcinogenic potential of iron has been shown, evidence from observational studies that have linked serum iron variables and cancer outcomes has been inconsistent. Objective: We investigated whether higher iron concentrations increased risk of cancer outcomes. Design: A prospective examination of iron biomarkers as independent risk factors for cancer was assessed in 1597 men and 1795 women aged 25-79 y who participated in the 1994/1995 Busselton Health Survey and had relevant data, no history of cancer before the survey, and serum ferritin concentrations $20 mg/L. Follow-up for incident cancers and death from cancer was available to 2010. Proportional hazards regression modeling was performed to investigate if iron status predicted cancer incidence and mortality. Results: After adjustments for age, smoking, drinking, anthropometric and biochemical variables, or menopausal status (breast cancer), higher serum iron concentrations and transferrin saturation were associated with increased risks of incident nonskin cancer [HR for iron: 1.83 (95% CI: 1.21, 2.76; P , 0.01); HR for transferrin saturation: 1.68 (95% CI: 1.18, 2.38; P , 0.01)] including breast cancer [HR for iron: 2.45 (95% CI:1.12, 5.34; P , 0.05); HR for transferrin saturation: 1.90 (95% CI:1.02, 3.56; P , 0.05)] in women. Transferrin saturation was also associated with a greater risk of cancer death (HR: 2.48; 95% CI: 1.28, 4.82; P , 0.01). In men, higher iron concentrations were associated with reduced risks of incident nonskin cancer (HR: 0.65; 95% CI: 0.42, 0.99; P , 0.05) including colorectal cancer (HR: 0.34; 95% CI: 0.12, 0.95; P , 0.05). There was no association between serum iron and colorectal cancer risk in women. Serum ferritin was not associated with cancer risk or cancer death. Conclusions: Higher transferrin saturation or serum iron concentrations were associated with increased nonskin cancer risk and increased risk of cancer death. Conversely, in men, higher serum iron concent
Original languageEnglish
Pages (from-to)736-742
JournalAmerican Journal of Clinical Nutrition
Volume104
Issue number3
Early online date3 Aug 2016
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Transferrin
Ferritins
Iron
Serum
Neoplasms
Colorectal Neoplasms
Breast Neoplasms
Health Surveys
Drinking
Observational Studies
Biomarkers
Smoking

Cite this

@article{fc94050526324d7fb5798aedb6dae961,
title = "Higher concentrations of serum iron and transferrin saturation but not serum ferritin are associated with cancer outcomes",
abstract = "{\circledC} 2016 American Society for Nutrition.Background: Although the carcinogenic potential of iron has been shown, evidence from observational studies that have linked serum iron variables and cancer outcomes has been inconsistent. Objective: We investigated whether higher iron concentrations increased risk of cancer outcomes. Design: A prospective examination of iron biomarkers as independent risk factors for cancer was assessed in 1597 men and 1795 women aged 25-79 y who participated in the 1994/1995 Busselton Health Survey and had relevant data, no history of cancer before the survey, and serum ferritin concentrations $20 mg/L. Follow-up for incident cancers and death from cancer was available to 2010. Proportional hazards regression modeling was performed to investigate if iron status predicted cancer incidence and mortality. Results: After adjustments for age, smoking, drinking, anthropometric and biochemical variables, or menopausal status (breast cancer), higher serum iron concentrations and transferrin saturation were associated with increased risks of incident nonskin cancer [HR for iron: 1.83 (95{\%} CI: 1.21, 2.76; P , 0.01); HR for transferrin saturation: 1.68 (95{\%} CI: 1.18, 2.38; P , 0.01)] including breast cancer [HR for iron: 2.45 (95{\%} CI:1.12, 5.34; P , 0.05); HR for transferrin saturation: 1.90 (95{\%} CI:1.02, 3.56; P , 0.05)] in women. Transferrin saturation was also associated with a greater risk of cancer death (HR: 2.48; 95{\%} CI: 1.28, 4.82; P , 0.01). In men, higher iron concentrations were associated with reduced risks of incident nonskin cancer (HR: 0.65; 95{\%} CI: 0.42, 0.99; P , 0.05) including colorectal cancer (HR: 0.34; 95{\%} CI: 0.12, 0.95; P , 0.05). There was no association between serum iron and colorectal cancer risk in women. Serum ferritin was not associated with cancer risk or cancer death. Conclusions: Higher transferrin saturation or serum iron concentrations were associated with increased nonskin cancer risk and increased risk of cancer death. Conversely, in men, higher serum iron concent",
author = "Chua, {Anita C. G.} and Knuiman, {Matthew W.} and Debbie Trinder and Divitini, {Mark L.} and J.K. Olynyk",
year = "2016",
month = "9",
doi = "10.3945/ajcn.115.129411",
language = "English",
volume = "104",
pages = "736--742",
journal = "The American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "3",

}

TY - JOUR

T1 - Higher concentrations of serum iron and transferrin saturation but not serum ferritin are associated with cancer outcomes

AU - Chua, Anita C. G.

AU - Knuiman, Matthew W.

AU - Trinder, Debbie

AU - Divitini, Mark L.

AU - Olynyk, J.K.

PY - 2016/9

Y1 - 2016/9

N2 - © 2016 American Society for Nutrition.Background: Although the carcinogenic potential of iron has been shown, evidence from observational studies that have linked serum iron variables and cancer outcomes has been inconsistent. Objective: We investigated whether higher iron concentrations increased risk of cancer outcomes. Design: A prospective examination of iron biomarkers as independent risk factors for cancer was assessed in 1597 men and 1795 women aged 25-79 y who participated in the 1994/1995 Busselton Health Survey and had relevant data, no history of cancer before the survey, and serum ferritin concentrations $20 mg/L. Follow-up for incident cancers and death from cancer was available to 2010. Proportional hazards regression modeling was performed to investigate if iron status predicted cancer incidence and mortality. Results: After adjustments for age, smoking, drinking, anthropometric and biochemical variables, or menopausal status (breast cancer), higher serum iron concentrations and transferrin saturation were associated with increased risks of incident nonskin cancer [HR for iron: 1.83 (95% CI: 1.21, 2.76; P , 0.01); HR for transferrin saturation: 1.68 (95% CI: 1.18, 2.38; P , 0.01)] including breast cancer [HR for iron: 2.45 (95% CI:1.12, 5.34; P , 0.05); HR for transferrin saturation: 1.90 (95% CI:1.02, 3.56; P , 0.05)] in women. Transferrin saturation was also associated with a greater risk of cancer death (HR: 2.48; 95% CI: 1.28, 4.82; P , 0.01). In men, higher iron concentrations were associated with reduced risks of incident nonskin cancer (HR: 0.65; 95% CI: 0.42, 0.99; P , 0.05) including colorectal cancer (HR: 0.34; 95% CI: 0.12, 0.95; P , 0.05). There was no association between serum iron and colorectal cancer risk in women. Serum ferritin was not associated with cancer risk or cancer death. Conclusions: Higher transferrin saturation or serum iron concentrations were associated with increased nonskin cancer risk and increased risk of cancer death. Conversely, in men, higher serum iron concent

AB - © 2016 American Society for Nutrition.Background: Although the carcinogenic potential of iron has been shown, evidence from observational studies that have linked serum iron variables and cancer outcomes has been inconsistent. Objective: We investigated whether higher iron concentrations increased risk of cancer outcomes. Design: A prospective examination of iron biomarkers as independent risk factors for cancer was assessed in 1597 men and 1795 women aged 25-79 y who participated in the 1994/1995 Busselton Health Survey and had relevant data, no history of cancer before the survey, and serum ferritin concentrations $20 mg/L. Follow-up for incident cancers and death from cancer was available to 2010. Proportional hazards regression modeling was performed to investigate if iron status predicted cancer incidence and mortality. Results: After adjustments for age, smoking, drinking, anthropometric and biochemical variables, or menopausal status (breast cancer), higher serum iron concentrations and transferrin saturation were associated with increased risks of incident nonskin cancer [HR for iron: 1.83 (95% CI: 1.21, 2.76; P , 0.01); HR for transferrin saturation: 1.68 (95% CI: 1.18, 2.38; P , 0.01)] including breast cancer [HR for iron: 2.45 (95% CI:1.12, 5.34; P , 0.05); HR for transferrin saturation: 1.90 (95% CI:1.02, 3.56; P , 0.05)] in women. Transferrin saturation was also associated with a greater risk of cancer death (HR: 2.48; 95% CI: 1.28, 4.82; P , 0.01). In men, higher iron concentrations were associated with reduced risks of incident nonskin cancer (HR: 0.65; 95% CI: 0.42, 0.99; P , 0.05) including colorectal cancer (HR: 0.34; 95% CI: 0.12, 0.95; P , 0.05). There was no association between serum iron and colorectal cancer risk in women. Serum ferritin was not associated with cancer risk or cancer death. Conclusions: Higher transferrin saturation or serum iron concentrations were associated with increased nonskin cancer risk and increased risk of cancer death. Conversely, in men, higher serum iron concent

U2 - 10.3945/ajcn.115.129411

DO - 10.3945/ajcn.115.129411

M3 - Article

VL - 104

SP - 736

EP - 742

JO - The American Journal of Clinical Nutrition

JF - The American Journal of Clinical Nutrition

SN - 0002-9165

IS - 3

ER -